Brief: Axsome Therapeutics Initiates Clarity Phase 3 Trial Of Solriamfetol In Adults With Major Depressive Disorder
24/02/2026 12:09
Feb 24 (Reuters) - Axsome Therapeutics Inc AXSM.O: AXSOME THERAPEUTICS INITIATES CLARITY PHASE 3 TRIAL OF SOLRIAMFETOL IN ADULTS WITH MAJOR DEPRESSIVE DISORDER WITH EXCESSIVE DAYTIME SLEEPINESS SYMPTOMS Source text: ID:nGNX7x4LNc Further company coverage: AXSM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axsome Therapeutics
See all newsUS RESEARCH ROUNDUP-Bright Minds Biosciences, Marvell Technology, Oracle Corporation
Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi
US RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Axsome Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Axsome Therapeutics Q2 revenue rises on AUVELITY growth